Biomerica (BMRA) Stock Price, News & Analysis

Company Overview

Biomerica, Inc. is a developer, manufacturer and marketer of in vitro diagnostic tests for clinical diagnostic, life science research and food safety applications. The company’s product portfolio includes enzyme-linked immunosorbent assays (ELISAs), lateral flow immunoassays, point-of-care devices and specialty reagents designed to aid in the detection and monitoring of gastrointestinal, metabolic and autoimmune conditions. Biomerica’s diagnostics are used by hospitals, clinical and reference laboratories, and research institutions seeking solutions for early disease detection and patient management.

Key offerings from Biomerica include serological tests for celiac disease and gluten intolerance, quantitative assays for colorectal cancer screening markers such as M2-PK, and a range of point-of-care kits for metabolic monitoring. The company also produces food safety test kits capable of detecting allergens and gluten residues in food products, serving the needs of food manufacturers and regulatory agencies. Its proprietary testing platforms are designed to deliver rapid, reliable results with user-friendly workflows suitable for both centralized and decentralized laboratory settings.

Founded in the late 1970s and headquartered in Irvine, California, Biomerica maintains a network of direct sales representatives in the United States as well as partnerships with distributors across Europe, Asia and Latin America. The company pursues regulatory clearances such as CE marking and FDA approvals to support its global market expansion. Biomerica’s manufacturing facilities are configured to meet quality standards including ISO 13485, enabling scalable production of diagnostic kits and reagents.

Biomerica is managed by a leadership team with experience in diagnostics research, regulatory affairs and commercial operations. The company continues to invest in product development and strategic collaborations aimed at broadening its assay pipeline and addressing unmet clinical needs. Through ongoing innovation and a focus on building international distribution channels, Biomerica seeks to strengthen its position in the growing in vitro diagnostics market.

Key Stats

• Today's Range: $2.17 to $2.22
• 50-Day Range: $1.92 to $2.21
• 52-Week Range: $1.87 to $4.60
• Volume: 13,069 shs
• Average Volume: 20,930 shs
• Market Capitalization: $6.72 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.00
• Consensus Rating: Sell

Biomerica Stock Analysis - MarketRank™

Biomerica scored higher than 48% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.7 / 5
• Analyst Rating: Sell

Consensus Rating

Biomerica has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

Biomerica has a consensus price target of $9.00, representing about 313.8% upside from its current price of $2.18.

Amount of Analyst Coverage

Biomerica has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Biomerica is -2.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Biomerica is -2.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Biomerica has a P/B Ratio of 1.35. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.41% of the float of Biomerica has been sold short.

Short Interest Ratio / Days to Cover

Biomerica has a short interest ratio ("days to cover") of 2.05, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Biomerica has recently decreased by 16.97%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Biomerica does not currently pay a dividend.

Dividend Growth

Biomerica does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.77

News Sentiment

Biomerica has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Biomerica this week, compared to 2 articles on an average week.

Search Interest

3 people have searched for BMRA on MarketBeat in the last 30 days.

MarketBeat Follows

3 people have added Biomerica to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Biomerica insiders have not sold or bought any company stock.

Percentage Held by Insiders

18.00% of the stock of Biomerica is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

22.28% of the stock of Biomerica is held by institutions.

BMRA Stock Analysis - Frequently Asked Questions

How have BMRA shares performed this year?

Biomerica's stock was trading at $2.52 at the beginning of 2026. Since then, BMRA stock has decreased by 13.7% and is now trading at $2.1750.

How were Biomerica's earnings last quarter?

Biomerica, Inc. (NASDAQ:BMRA) announced its earnings results on Monday, April, 13th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.20) by $0.76. The business earned $0.99 million during the quarter, compared to analyst estimates of $3.63 million. Biomerica had a negative trailing twelve-month return on equity of 98.14% and a negative net margin of 96.49%.

When did Biomerica's stock split?

Shares of Biomerica reverse split on the morning of Monday, April 21st 2025.The 1-8 reverse split was announced on Wednesday, April 16th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 18th 2025. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split.

How do I buy shares of Biomerica?

Shares of BMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Biomerica own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Biomerica investors own include Pfizer (PFE), Gilead Sciences (GILD), AT&T (T), NIO (NIO), ExxonMobil (XOM), Avino Silver & Gold Mines (ASM) and Bristol Myers Squibb (BMY).

Company Calendar

• Last Earnings: 4/13/2026
• Today: 5/07/2026
• Fiscal Year End: 5/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BMRA
• CIK: 73290
• Web: www.biomerica.com
• Phone: (949) 645-2111
• Fax: 949-553-1231
• Employees: 60
• Year Founded: 1971

Price Target and Rating

• Average Price Target for Biomerica: $9.00
• High Price Target: $9.00
• Low Price Target: $9.00
• Potential Upside/Downside: +313.8%
• Consensus Rating: Sell
• Rating Score (0-4): 1.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.89)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$4.97 million
• Net Margins: -96.49%
• Pretax Margin: -96.02%
• Return on Equity: -98.14%
• Return on Assets: -70.42%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.64
• Quick Ratio: 1.59

Sales & Book Value

• Annual Sales: $5.31 million
• Price / Sales: 1.27
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.61 per share
• Price / Book: 1.35

Miscellaneous

• Outstanding Shares: 3,090,000
• Free Float: 2,534,000
• Market Cap: $6.72 million
• Optionable: No Data
• Beta: 0.28